In a byline published by Life Science Daily News, Helio Genomics CEO Dr. Bharat Tewarie argues that the gap in liver cancer outcomes is not a failure of science, but a failure of the system meant to connect scientific progress to the patients who need it most.
The disconnect is stark. AASLD guidelines have long recommended surveillance every six months for high-risk patients, and when liver cancer is found early, five-year survival can reach 70 percent. Yet 80 to 90 percent of eligible patients are not screened at the recommended intervals, even as U.S. liver cancer incidence has tripled since 1980 and mortality has more than doubled.
Dr. Tewarie examines why ultrasound-based surveillance falls short in practice. A meta-analysis in Gastroenterology found that ultrasound alone detected about 47 percent of liver cancers at an early stage, dropping to 29 percent in patients with obesity-related liver disease. Beyond sensitivity, the operational burden of scheduling imaging, arranging transportation, taking time off work, and obtaining insurance preauthorization drives low adherence, making this a systems problem rather than a patient behavior problem.
He then makes the case for blood-based testing, which can happen during a routine primary care visit without a specialist or a dedicated imaging suite, and for AI-driven multi-analyte platforms like HelioLiver that combine cfDNA methylation patterns, protein biomarkers, and patient demographics rather than relying on a single marker such as AFP.
In the prospective CLiMB trial — nearly 2,000 patients across roughly 42 U.S. sites, published in the Journal of Hepatology — HelioLiver detected more early-stage liver cancers than ultrasound alone.
His closing point: a diagnostic innovation that does not reach the patient produces no clinical benefit, regardless of its sophistication.
View source version on lifesciencedaily.news.